Genetic alterations in urothelial bladder carcinoma: An updated review

Cancer

Volumn 106, Issue 6, 2006, Pages 1205-1216

  Mhawech Fauceglia, Paulette ^a   Cheney, Richard T ^a   Schwaller, Juerg ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Genetic alterations; Oncogenes; Progression pathways; Tumor suppressor genes; Urothelial bladder carcinoma

Indexed keywords

AURORA A KINASE; CD9 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FRAGILE HISTIDINE TRIAD PROTEIN; GEFITINIB; GENE PRODUCT; ONCOPROTEIN; PROTEIN P53; PROTEIN P63; RAF PROTEIN; TRIPLE FUNCTION DOMAIN PROTEIN; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; BLADDER PAPILLOMA; CANCER STAGING; CARCINOMA IN SITU; CD9 GENE; CELL ADHESION; CHROMOSOME 20Q; CHROMOSOME 5P; CHROMOSOME ABERRATION; CLINICAL TRIAL; DRUG TARGETING; DYSPLASIA; EXTRACELLULAR MATRIX; FGFR3 GENE; FHIT GENE; GENE; GENE MUTATION; HUMAN; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; RAF1 GENE; REVIEW; SOLID TUMOR; STK15 GENE; TRIO GENE; TSC1 GENE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; UROGENITAL TRACT TUMOR;

GENES, TUMOR SUPPRESSOR; HUMANS; MUTATION; ONCOGENE PROTEINS; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 33644841931     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.21743     Document Type: Review

References (101)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.
2. Borden LS Jr., Clark PE, Hall MC. Bladder cancer. Curr Opin Oncol. 2004;16:257-262.
3. Soloway MS, Sofer M, Vaidya A. Contemporary management of Stage 1 transitional cell carcinoma of the bladder. J Urol. 2002;167:1573-1583.
4. Holmang MS, Hedelin H, Anderstrom C, Holmberg E, Johansson SL. The importance of the depth of invasion in Stage T1 bladder carcinoma: a retrospective cohort study. J Urol. 1997;157:800-804.
5. Smith JA, Labasky RF, Cockett ATK, Fracchia JA, Montie JE, Rowland RG. Bladder cancer guidelines panel summary report of the management of nonmuscle invasive bladder cancer (Stages Ta, T1, and Tis). J Urol. 1999;162:1697-1701.
6. Simon R, Burger H, Brinkschmidt C, Bocker W, Hertle L, Terpe H-J. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J Pathol. 1998; 185:345-351.
7. Richter J, Jiang F, Gorog J-P, et al. Marked genetic differences between Stage pTa and Stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res. 1997;57:2860-2864.
8. Richter J, Beffa L, Wagner U, et al. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol. 1998;153:1615-1621.
9. Prat E, Bernues M, Caballin R, Egozcue J, Gelabert A, Miro R. Detection of chromosomal imbalances in papillary bladder tumors by comparative genomic hybridization. Urology. 2001;57:986-992.
10. Richter J, Wagner U, Schraml P, et al. Chromosomal imbalances are associated with a high risk of progression in early invasive (pT1) urinary bladder cancer. Cancer Res. 1999;59:5687-5691.
11. Simon R, Burger H, Semjonow A, Hertle L, Terpe H-J, Nocker W. Patterns of chromosomal imbalances in muscle invasive bladder cancer. Int J Oncol. 2000;17:1025-1029.
12. Bruch J, Wohr G, Hautmann R, et al. Chromosomal changes during progression of transitional cell carcinoma of the bladder and delineation of the amplified interval on chromosome arm 8q. Genes Chromosomes Cancer. 1998;23:167-174.
13. Yang A, Kaghad M, Wang Y, et al. P63, a p53 homolog at 3q27-29, encodes multiple products with transactivation, death-inducing, and dominant-negative activities. Mol Cell. 1998;2:305-316.
14. Park B-J, Lee S-J, Kim JI, et al. Frequent alteration of p63 expression in human primary bladder carcinoma. Cancer Res. 2000;60:3370-3374.
15. Urist MJ, Di Como CJ, Lu M-L, et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol. 2002;161:1199-1206.
16. Koga F, Kawakami S, Fuji Y, et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res. 2003;9:5501-5507.
17. Patturajan M, Nomoto S, Sommer M, et al. Delta-N p63 induces B-catenin nuclear accumulation and signaling. Cancer Cell. 2002;1:369-379.
18. Yarden Y, Sliwkowiski MX. Untangling the ErbB signaling network. Natl Rev Mol Cell Biol. 2001;2:127-137.
19. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res. 2001;7:1957-1962.
20. Junttila TT, Laato M, Vahlberg T, et al. Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reserve transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res. 2003;9:5346-5357.
21. Janmaat ML, Giaccone G. The epidermal growth factor receptor pathway and its inhibition as anticancer therapy. Drugs Today. 2003;39(Suppl C):61-80.
22. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163-1167.
23. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small lung cancer to gefitinib. N Engl Med. 2004;350:2129-2139.
24. Dominguez-Escrig JL, Kelly JD, Neal DE, King SM, Davies BR. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res. 2004; 10:4874-4884.
25. McHugh LA, Griffiths TR, Kriajevska M, Symonds RP, Mellon JK. Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer. Urology. 2004;63:619-624.
26. Kruger S, Weitsch G, Buttner H, et al. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol. 2002; 21:981-987.
27. Ohta JI, Miyoshi Y, Uemura H, et al. Fluorescence 'hybridization evaluation of c-erbB-2 gene amplification and chromosomal anomalies in bladder cancer. Clin Cancer Res. 2001;7:2463-2467.
28. Latif Z, Watters AD, Dunn I, Grigor K, Underwood MA, Barlett JM. HER2/neu gene amplification and protein overexpression in G3pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Eur J Cancer. 2004;40:56-63.
29. Cahill DP, Lengauer C, Yu J, et al. Mutations of mitotic checkpoint genes in human cancers. Nature. 1998;392:300-303.
30. Ducat D, Zheng Y. Aurora kinases in spindle assembly and chromosome segregation. Exp Cell Res. 2004;301:60-67.
31. Fraizer GC, Diaz MF, Lee IL, Grossman HB, Sens S. Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol. 2004;25:1631-1639.
32. Katayama H, Sasai K, Kawai H, et al. Phosphorylation by Aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet. 2004;36:55-62.
33. Sen S, Zhou H, Zhang R-D, et al. Amplification/overexpression of a mitotic kinase gene in human bladder cancer. J Natl Cancer Inst. 2002;94:1320-1329.
34. Simon R, Atefy R, Wagner U, et al. HER-2 and TOP2A co-amplification in urinary bladder cancer. Int J Cancer. 2003; 107:764-772.
35. Tamatani T, Hattori K, Iyer A, Tamatani K, Oyasu R. Hepatocyte growth factor is an invasion/migration factor of rat urothelial carcinoma cells in vitro. Carcinogenesis. 1999;20:957-962.
36. Cheng H-L, Trink B, Tzai T-S, et al. Overexpression of c-met as prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation. J Clin Oncol. 2002;20:1544-1550.
37. Guo Z, Linn JF, Wu G, et al. CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer. Nat Med. 2004;10:374-381.
38. Dumler I, Weis A, Mayboroda OA, et al. The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J Biol Chem. 1998;273:315-321.
39. Zheng M, Simon R, Mirlacher M, et al. TRIO amplification and abundant mRNA expression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Am J Pathol. 2004;165:63-69.
40. Oeggerli M, Tomovska S, Shraml P, et al. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oncogene. 2004;23:5616-5623.
41. Christoph F, Scmidt B, Schmidt-drager BJ, Schluz WA. Overexpression and amplification of the c-myc gene in human urothelial carcinoma. Int J Cancer. 1999;84:169-173.
42. Mahdy E, Pan Y, Wang N, Malmstrom PU, Ekman P, Bergerheim U. Chromosome 8 numerical aberration and c-myc copy number gain in bladder cancer are linked to stage and grade. Anticancer Res. 2001;21:3167-3173.
43. Lipponen PK. Expression of c-myc protein is related to cell proliferation and expression of growth factor receptors in transitional cell bladder cancer. J Pathol. 1995;175:203-210.
44. Simon R, Richter J, Wagner U, et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res. 2001;61:4514-4519.
45. Gracia-Espana A, Salazar E, Sun TT, Wu XR, Pellicer A. Differential expression of cell cycle regulators in phenotypic variants of transgenically induced bladder tumors: implications for tumor behavior. Cancer Res. 2005;65:1150-1157.
46. Watters AD, Latif Z, Forsyth A, et al. Genetic aberrations of c-myc and CCND1 in the development of invasive bladder cancer. Br J Cancer. 2002;87:654-658.
47. Zaharieva BM, Simon R, Diener PA, et al. High-throughput microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer. J Pathol. 2003;201:603-608.
48. Jahnson S, Karlsson MG. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma. Cancer. 2000;89:619-629.
49. Simon R, Struckmann K, Schraml P, et al. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene. 2002;21:2476-2483.
50. Knowles MA. What do we could do now: molecular pathology of bladder cancer. J Clin Pathol Mol Pathol. 2001;54:215-221.
51. Mhawech P, Greloz V, Oppikofer C, Szalay-Quinidoz I, Herrmann F. Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression. Cancer. 2004;100:2367-2375.
52. Richter J, Wagner U, Kononen J, et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol. 2000; 157:787-794.
53. Wagner U, Suess K, Luginbuhl T, et al. Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. J Pathol. 1999;188:44-50.
54. Ioachim E, Michael M, Stavropoulos NE, et al. Expression patterns of cyclin D1, E, and cyclin-dependent kinase inhibitors p21 (Waf1/Cip1) and p27 (Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features. Urol Int. 2004;73:65-73.
55. Chatterjee SJ, Datar R, Youssefzadeh D, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol. 2004;22:1007-1013.
56. Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22:1014-1024.
57. Del Pizzo JJ, Borkowski A, Jacobs SC, Kyprianou N. Loss of cycle regulators p27 (Kip-1) and cyclin E in transition cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol. 1999;155:1129-1136.
58. Hurst CD, Fiegler H, Carr P, Willimas S, Carter NP, Knowles MA. High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene. 2004;23:2250-2263.
59. Wada T, Louhelainen J, Hemminki K, et al. The prevalence of loss of heterozygosity in chromosome 3, including FHIT, in bladder cancer, using the fluorescent multiplex polymerase chain reaction. BJU Int. 2001;87:876-881.
60. Croce CM, Sozzi G, Huebner K. Role of FHIT in human cancer. J Clin Oncol. 1999;17:1618-1624.
61. Nishizaki M, Sasaki J-I, Fang B, et al. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res. 2004;64:5745-5752.
62. Roz L, Andriani F, Ferreira CG, Giaccone G, Sozzi G. The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression. Oncogene. 2004;23:9102-9110.
63. Vecchione A, Sevignani C, Gianieri E, et al. Inactivation of the FHIT gene favors bladder cancer development. Clin Cancer Res. 2004;10:7607-7612.
64. Baffa R, Gomella LG, Vecchione A, et al. Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am J Pathol. 2000;156:419-424.
65. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promotor methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 2001;61:8659-8663.
66. Skopelitou AS, Gloustianou G, Bai M, Huebner K. FHIT gene expression in human urinary bladder transitional cell carcinomas. In Vivo. 2001;15:169-173.
67. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol. 2004;22:4632-4642.
68. Chan MW, Chan LW, Tang NL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder patients. Clin Cancer Res. 2002;8:464-470.
69. Esteller M. DNA methylation and cancer therapy: new developments and expectations. Curr Opin Oncol. 2005;17:55-60.
70. Gilbert J, Gore SD, Herman JG, Carducci MA. The clinical application of targeting cancer through histone acetylation and hypomethylation [review]. Clin Cancer Res. 2004;10:4589-4596.
71. Sibley K, Cuthbert-Heavens D, Knowles MA. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene. 2001;20:686-691.
72. Munro NP, Knowles MA. Fibroblast growth factors and their receptors in transitional cell carcinoma. J Urol. 2003;169:675-682.
73. Sibley K, Stern P, Knowles MA. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumors. Oncogene. 2001;20:4416-4418.
74. Dai H, Holm R, Kristensen GB, Abeler VM, Borresen-Dale A-L, Helland A. Fibroblast growth factor receptor 3 (FGFR3)-analyses of the S249C mutation and protein expression in primary cervical carcinomas. Anal Cell Pathol. 2001;23:45-49.
75. Rieger-Christ KM, Mourtzinos A, Lee PJ, et al. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection. Cancer. 2003;98:737-744.
76. Billerey C, Chopin D, Aubriot-Lorton M-H, et al. Frequent FGFR3 mutations in papillary non-invasive bladder pTa tumors. Am J Pathol. 2001;158:1955-1959.
77. Van Rhijin BWG, Vis AN, Van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol. 2003;21:1912-1921.
78. Van Rhijn BWG, Lurkin I, Radvanyi F, Kirkles WJ, Van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res. 2001; 61:1265-1268.
79. Fich PW, He X, Kelly MJ, et al. Purification and molecular cloning of a secreted, frizzled-related antagonist of Wnt action. Proc Natl Acad Sci USA. 1997;94:6770-6775.
80. Stall FJ, Clevers HC. WNT signaling and haematopoesis. A WNT-WNT situation. Natl Rev Immunol. 2005;5:21-30.
81. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancers. Nat Genet. 2002;31:141-149.
82. Stoehr R, Wissmann C, Suzuki H, et al. Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest. 2004;84:465-478.
83. Wada T, Berggren P, Steineck G, et al. Bladder neoplasms-regions at chromosome 9 with putative tumor suppressor genes. Scand Urol Nephrol. 2003;37:106-111.
84. Willimas SV, Sibley KD, Davies AM, et al. Molecular genetic analysis of chromosome 9 candidate tumor-suppressor loci in bladder cancer cell lines. Genes Chromosomes Cancer. 2002;34:86-96.
85. Hornigold N, Devlin J, Davies AM, Aveyard JS, Habuchi T, Knowles MA. Mutation of the 9q34 gene TSC1 in sporadic bladder cancer. Oncogene. 1999;18:2657-2661.
86. Edwards J, Duncan P, Going JJ, Watters AD, Grigor KM, Barlett JMS. Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. J Pathol. 2002;196:380-385.
87. Adachi H, Igawa M, Shiina H, Urakami S, Shigeno K, Hino O. Human bladder tumors with 2-HIT mutations of the tumor suppressor gene TSC1 and decreased expression of p27. J Urol. 2003;170:601-604.
88. Sanchez-Carbayo M, Capodieci P, Cordon-Cardo C. Tumor suppressor role of KISS-1 in bladder cancer. Loss of KISS-1 expression is associated with bladder cancer progression and clinical outcome. Am J Pathol. 2003;162:609-617.
89. Su J-S, Arima K, Hasegawa M, et al. Decreased of KAI1 metastasis suppressor gene is a recurrence predictor in primary pTa and pT1 urothelial bladder carcinoma. Int J Urol. 2004;11:74-82.
90. Mhawech P, Herrmann F, Coassin M, Guillou L, Iselin CE. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression. Cancer. 2003;98:1649-1657.
91. Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson HF. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res. 2004; 10:3800-3806.
92. Natrajan R, Louhelainen J, Williams S, Laye J, Knowles M. High-resolution deletion mapping 15q13.2-q21.1 in transitional cell carcinoma of the bladder. Cancer Res. 2003;63:7657-7662.
93. Rao JY, Seligson D, Visapaa H, et al. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Cancer. 2002;95:1247-1257.
94. Byrne RR, Shariat SF, Brown R, et al. E-cadherin immunostaining of bladder transitional carcinoma, carcinoma in situ and lymph node metastases with long-term follow up. J Urol. 2001;165:1473-1479.
95. Chow N-H, Liu H-S, Chan S-H. The role of nm23-H1 in the progression of transitional cell bladder cancer. Clin Cancer Res. 2000;6:3595-3599.
96. Modlich O, Prisack H-B, Pitschle G, et al. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res. 2004;10:3410-3421.
97. Dyrskjot L, Thykjaer T, Kruhoffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet. 2003;33:90-96.
98. Sanchez-Carbayo M, Socci ND, Lozano JJ, et al. Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol. 2003;163:505-516.
99. Thykjaer T, Workman C, Kruhoffer M, et al. Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Res. 2001;61:2492-2499.
100. Spruck CH III, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 1994;54:784-788.
101. Van Rhijin G, van der Kwast TH, Vis AN, et al. FGFR3 and p53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 2004;64:1911-1914.